Roche’s Actemra Cuts Ventilator Need in COVID-19 Patients

Roche’s late-stage COVID-19 trial of Actemra (tocilizumab) showed the rheumatoid arthritis drug reduced the number of coronavirus patients who progressed to mechanical ventilation, suggesting it might be of benefit as a coronavirus treatment although the drug did not meaningfully lower mortality rates.
Source: Devices & Diagnostics Letter